{"id":"epirubicin-e","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity / cardiomyopathy"},{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"0a03c798-a652-4895-b29c-3b521a89ba42","title":"ELLENCE (EPIRUBICIN HYDROCHLORIDE) INJECTION, SOLUTION [PHARMACIA & UPJOHN COMPANY LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin is an anthracycline chemotherapy agent that intercalates between DNA base pairs and inhibits topoisomerase II, leading to DNA strand breaks and cell death. It is commonly used in combination chemotherapy regimens for solid tumors. The drug generates reactive oxygen species that further damage cancer cells.","oneSentence":"Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents cancer cell replication and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:15.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (early-stage and metastatic)"},{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Lymphomas"}]},"trialDetails":[{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT07320508","phase":"PHASE2","title":"Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2026-01-20","conditions":"Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin","enrollment":100},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT06964906","phase":"PHASE2","title":"Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-04","conditions":"ER+/HER2- Breast Cancer","enrollment":140},{"nctId":"NCT06795503","phase":"PHASE3","title":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02","conditions":"Triple-negative Breast Cancer","enrollment":1462},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT03281954","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2017-12-19","conditions":"Triple Negative Breast Cancer","enrollment":1550},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT02641847","phase":"PHASE2, PHASE3","title":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2016-01","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":503},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT05572983","phase":"PHASE2","title":"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-09-01","conditions":"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","enrollment":47},{"nctId":"NCT03286634","phase":"PHASE2","title":"ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016","status":"RECRUITING","sponsor":"National Hospital Organization Nagoya Medical Center","startDate":"2017-04-18","conditions":"Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer","enrollment":60},{"nctId":"NCT05341141","phase":"NA","title":"Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"Peking University","startDate":"2022-06-10","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02909751","phase":"PHASE2","title":"Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-09-14","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT00776724","phase":"PHASE3","title":"Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-05-29","conditions":"Breast Cancer, Chemotherapy","enrollment":166},{"nctId":"NCT03123770","phase":"PHASE4","title":"Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2016-12","conditions":"Breast Cancer","enrollment":384},{"nctId":"NCT02177552","phase":"PHASE2","title":"Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2014-06","conditions":"Esophageal Neoplasms, Stomach Neoplasms","enrollment":98},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT02694224","phase":"PHASE2","title":"Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2016-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT00424606","phase":"PHASE3","title":"Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2001-06","conditions":"Breast Cancer","enrollment":658},{"nctId":"NCT01989858","phase":"PHASE3","title":"ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2010-11","conditions":"Gastric Adenocarcinoma","enrollment":1180},{"nctId":"NCT00751868","phase":"PHASE2","title":"FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2008-09","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT00843934","phase":"PHASE2, PHASE3","title":"Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Nihon University","startDate":"2009-03","conditions":"Carcinoma, Hepatocellular","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ELLENCE®"],"phase":"marketed","status":"active","brandName":"Epirubicin (E)","genericName":"Epirubicin (E)","companyName":"Eye & ENT Hospital of Fudan University","companyId":"eye-ent-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents cancer cell replication and survival. Used for Breast cancer (early-stage and metastatic), Gastric cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}